MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
2017 ASH Symposium – Presentations Available Below

2017 ASH Symposium - Presentations Available Below

Claim Credits Now


Click the links below to view our presentations:

Myeloid Neoplasms with Germline Predisposition
Marcin W. Wlodarski and Charlotte M. Niemeyer

Clonal Cytopenia and Myeloid Neoplasms
Luca Malcovati, MD

Abnormalities of the Immune System and Inflammation in MDS Pathogenesis
Shahram Kordasti MSc(Med Imm), MD, PhD

Therapies for Higher Risk MDS Patients: Optimizing HMA Approaches and Use of Novel Agents
Rami Komrokji, MD

Maximizing Success: Optimizing Prognostication and Timing of Allogeneic Stem Cell Transplant for MDS
John Koreth, MBBS DPhil

Program Overview

Recent developments in our knowledge of the immune system, the bone marrow micro-environment and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objective

Upon completion of the educational activity, participants should be able to:

  • Describe the various stages of clonal hematopoietic evolution in the elderly
  • Identify the complex interplay between the MDS clone and its microenvironment
  • Describe molecular background, which plays a role in the dysregulation of the innate and adaptive immune system in MDS
  • Discuss both inherited and acquired genetic factors that contribute to MDS pathogenesis and influence prognosis
  • Describe the various processes of inflammation and oxidative stress that are associated with the development and (vasculitic) symptoms of MDS
  • Utilize objective response predictors and strategies to maximize the successful use of hypomethylating agents
  • Apply the objective prognostic factors and measures to identify the patients most suitable for allogeneic stem cell transplant, which may lead to better outcomes

Featured Faculty

Stephen Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida

Rena Buckstein, MD, FRCPC – Symposium Co-Chair

Director of MDS Research Program and Head of National MDS registry
Head, Hematology Site Group
Odette Cancer Center
Toronto, Canada

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Jude Fitzgibbon, PhD

Professor of Personalised Cancer Medicine
Queen Mary University of London
London, United Kingdom

Rami Komrokji, MD

Leukemia and MDS Section Head
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Shahram Kordasti, MD, PhD

King’s College Hospital and King’s College London
Department of Haematological Medicine
London, United Kingdom

John Koreth, MD, PhD

Associate Professor, Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute
Boston, Massachusetts

Luca Malcovati, MD

Associate Professor of Hematology
University of Pavia
Department of Hematology Oncology & Molecular Medicine
Pavia, Italy

Review answers to commonly asked questions or get answers to your questions from an MDS expert